Silence Therapeutics Plc ADR SLN

$19.81 0.00 (—)

Valuation

Market cap
1,231,271,000
Revenue TTM
$560,000
Net income TTM
$-88,610,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
-15,823.21%
Debt to equity
0.00

Trading

Volume
399,100
Avg volume
2,897,988
Day's range
$19.80 – $19.83
Shares out
62,154,000
Stochastic %K
66%
Beta
1.34
Analysts
Hold
Price target
$20.40

Price

Company profile

Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Divesiran (SLN124), which is in Phase 2 development for polycythemia vera, and SLN548 for complement-mediated renal diseases. It a...

Show more

Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Divesiran (SLN124), which is in Phase 2 development for polycythemia vera, and SLN548 for complement-mediated renal diseases. It also develops Zerlasiran (SLN360) for cardiovascular disease associated with elevated lipoprotein(a); SLN312 for dyslipidemia; SLN365 for hypercholesterolemia; and SLN098 for obesity. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, United Kingdom.

Industry
Biotechnology
Sector
Healthcare
Phone
44 20 3457 6900
Website
https://www.silence-therapeutics.com
Address
12 Hammersmith Grove, London, United Kingdom

Latest news

Stocktwits

shoc24 Nov 20, 5:31 PM
Been a crazy few weeks in the market but there is still opportunity if you're investing long term. $SLN is ranked #20 in healthcare momentum with a score of 85. I used Stock Meadow's scoring model. Build your own model and backtest it if you don't agree with mine.
0 replies
Merlintrader Nov 12, 8:59 PM
Latest company news for $SLN, Nov 12: Silence Therapeutics reported Q3 with 247.7 million dollars of cash at Sept 30 and R&D expenses down to 9.3 million. The divesiran Phase 2 SANRECO data get an oral presentation at ASH 2026. Full $SLN stock hub: https://www.merlintrader.com/silence-therapeutics-sln-stock-hub/ Not investment advice.
1 replies
focafoca99 Nov 12, 1:35 PM
$SLN announced its Q3 2026 financial results.
0 replies
StMichaelTwits Nov 7, 4:20 PM
$SLN $IONS Ions, you want your monies back..load up $SLN on a down day..they have the goods👉 LPa Phase 3 coming to a theater near you.💎
0 replies
StockSmallPenz Oct 21, 5:53 PM
$NVAX I guess that rumor was false and they acquired $SLN instead.
1 replies
STRelativeStrength Oct 21, 5:50 PM
$SLN undiscovered breakout with 558 watchers
0 replies
MCRB_BULL Oct 21, 9:40 AM
$MCRB $XBI $IBB $XBI up 3.65% while MCRB drops 3.72% yesterday? Basically red every day with NO meaningful bounce since Sept 3.🤦‍♂️ Rate-hike fears and the biotech bloodbath are contributing, but ~$23M market cap, BELOW CASH, no debt, and runway through at least March 2027? We shouldn't be THIS low when the pipeline could be worth multiples of today's valuation. Look at $SLN's chart from Sept 3 through its buyout. Nearly 50% bleeding, eerily similar price action. Not saying the situations are identical, but a collapsing chart doesn't mean the underlying assets lack strategic value.👀 Could prolonged negotiations be keeping a lid on the share price? A potential acquirer may benefit from weakness. Pure speculation, but worth considering. The pipeline didn't suddenly become worthless. At ~$23M, this valuation is difficult to reconcile with the potential asset value. The longer this stays pinned down, the more I wonder what happens when that pressure finally releases. Could get WILD🚀
2 replies
sSwSs Oct 20, 2:40 PM
$SLN — Silence Therapeutics' acquisition by Merck KgaA and significant share price surge dominated recent analyses.
0 replies